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A report on the inaugural symposium of the Hutchison/MRC
Research Centre, Cambridge, UK, 24-25 October 2002.
The Hutchison/MRC Research Centre was formally opened
this year. Its goal, as stated on its website [http://www.hutchi-
son-mrc.cam.ac.uk/], is to bring basic research into the prac-
tice of clinical oncology, and groups in the Centre (including
my own) hope, for example, to use an understanding of the
basic machinery of DNA replication and state-of-the-art
genomic technologies to screen for new mutations that lead
to a predisposition to cancer. Yet fundamental questions
about this strategy remain: whether we understand enough
biology to design anti-cancer strategies, whether transla-
tional research belongs in the academic setting, what the
impact of genome-wide studies will be on cancer diagnosis
and treatment, and whether scientists can now deliver on
their promises to medicine. 
What causes cancer? It has taken us nearly 40 years to
provide a partial answer to this superficially simple question.
A consensus is emerging that, more often than not, a combi-
nation of events is required for cancer formation: the gain of
expression of an oncogene that directs the cells to divide, the
loss of tumor suppressors that would otherwise inhibit
signals to replicate or guard the integrity of the genome,
and/or a defect in DNA replication or DNA repair. 
The basic biology of cancer 
The cell cycle  
It has sometimes been assumed that all we need to know
about the biology of cancer can be learnt from studies of the
biology of the cell-division cycle. Tim Hunt (Cancer
Research UK, Clare Hall, UK), one of the people who have
driven cell-cycle research, gave a presentation of the con-
cepts that underlie our understanding of cell proliferation
and a description of the molecular machineries that mediate
progression through the cell cycle. He ended, however, with
the controversial statement that cell-cycle regulators will
not be good drug targets in cancer therapy. Hunt’s view is
that cancer is a disease of development rather than cell divi-
sion. Targeting a cell’s developmental decision-makers will
allow therapies to act specifically on tumor cells, whereas
cell-cycle inhibitors will lack specificity, leading to the
unpleasant side-effects with which cancer patients are
already all too familiar. 
Kim Nasmyth (Institute of Molecular Pathology, Vienna,
Austria) was one of many speakers whose work suggests
that cell-cycle regulators are certainly worth investigating.
He described the molecular machinery that triggers the
release of sister-chromatid cohesion at the onset of
anaphase. Nasmyth used an apt analogy to describe the
intricate problem of getting each set of homologous chro-
matids to opposite ends of the dividing anaphase cell: two
blind men separating two sets of five pairs of colored socks,
with each man wanting to end up with five pairs of socks,
one pair of each color. Like the cell, the blind men solve the
problem by each taking one sock (chromatid) from each
pair, but whereas we can understand how they achieve this,
we have some way to go to understand how the cell
manages the analogous feat. Nasmyth described some very
nice experiments in yeast showing that each pair of sister
chromatids created by DNA replication in S phase are
embraced by a ring formed from the four-subunit protein
complex called cohesin. The trigger for separation seems to
be the degradation by the anaphase-promoting complex of
securin, an inhibitor of a cohesin protease called separase.
He showed that insertion into cohesin of sites for proteases
other than separase, and cleavage of these inserted sites, is
sufficient to cause the separation of homologous chro-
matids in yeast cells. Clearly, any defect in chromosome
partitioning that allows a daughter cell to acquire fewer or
more copies of each region of the genome will potentially
allow that cell to lose a tumor suppressor or gain an onco-
gene. The molecular details of anaphase differ between yeastand humans, but many of the proteins that regulate or
monitor sister-chromatid separation are known to be altered
in human cancer cells, suggesting that this pathway may rep-
resent a new route to therapies. 
DNA damage 
How does DNA damage contribute to the very first steps in
cancer? The work of Susan Gasser (University of Geneva,
Switzerland) addresses the machineries behind this funda-
mental question, focusing on the intra-S-phase checkpoint.
Checkpoints within the cell cycle serve to ensure the comple-
tion of one process before the next begins; the intra-S-phase
checkpoint prevents DNA replication through damaged
DNA. The very existence of this checkpoint has been hard to
prove, and it was really only hinted at because of the defec-
tive activation of other, G2/M phase checkpoints in cells har-
boring specific mutations in genes that regulate S phase.
Gasser has provided compelling evidence for the existence of
the intra-S-phase checkpoint and has begun to dissect it at
the molecular level. She explained that Orc2p, one of the
proteins responsible for loading the DNA-replication
machinery onto DNA, is required for the phosphorylation of
the checkpoint protein Rad53 when DNA is damaged during
S phase. This phosphorylation can still occur in Orc2-
deficient cells when the DNA-damaging treatment is applied
in G2 phase, suggesting that the phenomenon really is an
intra-S-phase event. 
At the molecular level, stalled replication forks closely
resemble damaged DNA. Why then doesn’t the cell respond
to cut DNA at replication forks as it would if the DNA were
genuinely damaged? We know that stalled replication forks
trigger the intra-S-phase checkpoint, whereas DNA damage
would trigger the G2/M-phase checkpoint. Gasser’s data
suggest that the threshold for G2/M checkpoint activation by
DNA damage is lower than the threshold for activation of the
intra-S-phase checkpoint, providing a mechanism that
allows cells to proceed through S phase even though replica-
tion forks could be confused with damaged DNA. The intra-
S-phase checkpoint signal appears to originate at the
replication fork, and Gasser showed data implicating the
DNA helicase Sgs1p as a stabilizer of DNA polymerases at
stalled replication forks, perhaps acting by maintaining the
single-stranded DNA template. A human homolog of Sgs1p
has been implicated in aging processes, as it is mutated in
Werner’s Syndrome, an aging syndrome that includes a pre-
disposition to cancer. It will be particularly interesting to
know whether the molecular basis of Sgs1 function is the
same in aging and in cancer.
Jan Hoeijmakers (Erasmus University, Rotterdam, The
Netherlands), who has also been instrumental in furthering
our understanding of the links between DNA repair and
cancer, similarly hinted at a link between aging (senescence)
and cancer. The studies of his group have focused on rela-
tively rare human genetic syndromes such as Xeroderma
Pigmentosum, trichothiodystrophy (TTD) and Cockayne’s
syndrome, all of which predispose to cancer. The genes
whose mutations lead to these diseases have generally
proved to encode proteins that normally participate in
nucleotide-excision repair of helix-distorting DNA damage.
The most recently studied of these proteins, those involved
in TTD, may also provide a link between DNA repair and
aging. Hoeijmakers suggested that this may be due to
decreased cell function following loss of transcription caused
by inappropriate handling of transcription-blocking DNA
damage in TTD cells, leading to cellular senescence.
DNA synthesis 
The spatial and temporal control of DNA synthesis was
described by Ed Harlow (Harvard Medical School, Boston,
USA). Using primary cells, rather than the cultured cell lines
that are most often used for this type of study, Harlow
showed that bromodeoxyuridine (BrdU) can be used to mark
foci of DNA replication in the nucleus. Such sites have been
missed previously, at least in part because the immortaliza-
tion of cells required to produce a cell line alters the pattern
of DNA replication: in fact, foci of replication are almost
completely lost even in very early passage cells. Harlow also
showed that, like BrdU incorporation, the tumor suppressor
protein retinoblastoma (pRb) is localized to a few large foci
in the nucleus early in S phase (a pattern called the focal
phenotype) and in a large number of smaller foci as DNA
replication nears completion (the distributed phenotype).
Indeed, proteins that interact with pRb, such as histone
deacetylases and the transcription factors E2F and p130, all
colocalize with the polymerase subunit PCNA at sites of
BrdU incorporation in early S-phase nuclei, and this pattern
is lost in late S phase. 
In an attempt to characterize these pRb/BrdU foci, Harlow
turned to a comprehensive list of other proteins known to
bind to pRb (published by E.J. Morris and N.J. Dyson in
2001). One such protein is lamin A, a structural protein of
the nucleus. When Harlow looked at pRb in lamin A-/-
mouse embryonic fibroblasts, the pRb protein was found to
be destabilized, although RNA levels were not affected; pRb
was not even in the nucleus, indicating that lamin A may
have a role in the establishment or maintenance of sites of
DNA replication. These could conceivably correspond to
DNA replication ‘factories’, through which replicating chro-
matin would spool. Like cells containing mutant pRb, lamin-
A-deficient fibroblasts fail to arrest after  irradiation,
indicating that the presence of pRb at the sites of DNA repli-
cation may play a role in checkpoint arrest following DNA
damage. Intriguingly, DNA replication may also respond to
cell density: in densely grown populations, BrdU incorpora-
tion remains focal even late in S phase, in contrast to the
previously described situation in sparsely grown cells. If this
observed difference reflects a biological reality, it may corre-
spond to a difference between tumor and normal cells that
could be exploited in cancer treatment. 
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Roger Brent (Molecular Sciences Institute, Berkeley, USA)
described two approaches that he is taking to look at molec-
ular interactions. First, he outlined the design of completely
novel ways of detecting molecular interactions in single cells,
so that the contribution of cell-to-cell variability to the
behavior of populations of cells can start to be measured.
Brent described the work of the ‘Alpha project’
[http://www.molsci.org/alpha], a collaboration between
groups at different institutes that has so far used the tran-
scriptional output of the yeast pheromone signaling pathway
to measure the effects on signal transduction of perturba-
tions to the yeast cells. Second, Brent has been developing
methods for the detection of single molecules of protein. A
single molecule of DNA can be reliably detected 3 times out
of 10, and a single molecule of RNA can be reliably detected
90% of the time; there has not been any technology that
would allow detection of single protein molecules every time.
Peptide aptamers are recognition reagents that bind specifi-
cally to a given protein. Brent and coworkers have devised a
method of covalently linking each peptide aptamer to the
DNA that encodes it, creating reagents he calls ‘tadpoles’.
Because the DNA can be amplified by PCR, this should allow
the detection of single molecules of protein, even in complex
samples, bringing the sensitivity of protein detection to the
levels achieved for the detection of RNA or DNA.
From cancer cells to cancer genes 
What can genome-wide studies contribute to our understand-
ing of cancer? Nick Lemoine (Imperial College Faculty of
Medicine, London, UK) described the range of technologies
available and some of their clinical applications. Laser-
capture microdissection can be used to isolate individual cells
or small, suspicious lesions from patient samples. The
genomes of these cells can then be subjected to mutational
analysis, DNA fingerprinting, microarrays or two-dimen-
sional gel proteomic analysis. The goal of these studies is both
to devise new ways to classify tumors and to seek clues to the
likely response of each patient to chemotherapy. The results
can be intriguing; for example, of the 245 genes whose
expression changed in response to treatment with the EGF-
receptor antagonist Iressa, none encoded the EGF-receptor! 
Lemoine then highlighted a bottleneck in drug discovery:
the validation of potential drug targets. He described the
development of a very elegant approach to inhibiting the
expression of individual genes, called Gene ICE. Simply put,
triplex-forming oligonucleotides (TFOs) are used to bind
specifically to DNA sequences present in the upstream reg-
ulatory regions of target genes. Covalently bound to the
TFOs are 29 amino acids from the Mad transcription factor
that are sufficient to recruit transcriptional co-repressors,
including histone deacetylases, leading to gene silencing.
This technology should allow us to determine the relevance
of any gene changes identified in molecular profiling by
microarrays and also to determine whether any of the
altered genes are good drug targets. If Gene ICE cures cellu-
lar models of a disease, drugs that target that protein are
likely to cure that disease in humans.
‘Cancer-omics’ 
Olli Kallioniemi (now at VTT Biotechnology, Turku, Finland)
started by warning us that the ‘omics’ craze obscures the fact
that basic biological discoveries remain key, but then took us
on a breath-taking tour of high-throughput technologies for
translational cancer research in the post-genomic era. His
opening question was: can large-scale profiling lead us to a
single validated drug target? His answer was that it probably
can, if one first integrates DNA, RNA and protein profiling
data to identify the most promising candidates, then uses
high-throughput clinical studies to confirm clinical rele-
vance before using high-throughput cell-based studies in
hypothesis-driven experiments to validate them. Thus, array
comparative genome hybridization (array CGH) can be used
to look at genome amplification, while DNA or oligonu-
cleotide microarrays can reveal levels of transcription of can-
didate genes. In this way, Kallioniemi’s group has produced
high-resolution overviews of the genomes of breast and
prostate cancer cells that have allowed him to identify new
amplifications and deletions. This approach detects 90% of
the abnormalities seen in conventional CGH but also detects
many others that were previously missed. Kallioniemi also
briefly described a new technique, in which inhibition of the
nonsense-mediated RNA-decay pathway allows the accumu-
lation of transcripts encoding mutated or truncated proteins.
This idea has allowed the detection of known truncations in
cell lines, but it is not yet known whether it will allow the
identification of any novel cancer-associated mutations. 
From cancer genes to pathways to cancer 
Ed Liu (Genome Institute of Singapore) emphasized the point
made by others that large-scale microarray data are more
useful in the identification of important pathways than of
identifying individual genes. His group has studied thyroid
hormone signaling and uncovered an unexpected role for the
pathway downstream of the Wnt signaling molecule. His data
showed that increased thyroid hormone signaling coordi-
nately decreased activity of members of the Wnt pathway (an
anti-carcinogenic effect), while decreased levels of thyroid
hormone appeared to increase the activity of the Wnt
pathway, which could lead to carcinogenesis. These observa-
tions were confirmed biochemically. Consistent with Liu’s
microarray-driven hypothesis, it has previously been
observed that a dominant-negative thyroid-hormone recep-
tor (v-ErbA) is carcinogenic in chickens and that mutants of
the receptor that cannot bind DNA are frequently associated
with liver cancer in humans. 
Liu then went on to show that the molecular profiles of tumors
can be a signature of the genetic points of origin of the cancer.
Using transgenic mouse cancer models, Liu showed that
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Genome Biology 2003, 4:305cancers caused by oncogenes in the same pathway (such as
genes encoding Erb-B2, its receptor Neu, and the small
GTPase Ras) give rise to microarray profiles that can be clus-
tered together and that are distinct from cancers caused by
oncogenes on different pathways (such as SV40 large
T antigen and the transcription factor Myc). When examining
human breast cancers, he found that the most powerful
factor that leads to distinct expression profiles is the pres-
ence or absence of estrogen receptor (ER) expression: the
expression profiles of ER-negative and ER-positive breast
cancers cluster separately. In addition, ER-positive cancers
can be divided by molecular profiling into two prognostic
groups - one with an excellent outcome and the other with a
rate of relapse-free survival only half as high. These observa-
tions are remarkably consistent with several other studies,
and comparison of the gene lists from different studies iden-
tifies specific prognosis-associated genes. This is likely to be
the first example in which microarrays are brought into clin-
ical practice; it will allow identification of the large minority
of patients who will benefit from chemotherapy following
radiation or surgery, avoiding the current problem that some
patients who do not actually need them are given drugs with
unpleasant side-effects. 
Beyond the single cell 
Cell-cell communication 
Fiona Watt (Cancer Research UK, London, UK) spoke on
the role of the integrin extracellular-matrix receptors in the
formation and development of epithelial cancers called
squamous cell carcinomas. She explained that integrins
normally regulate epithelial differentiation by sending a
‘do not differentiate’ message to the cell; this signal can
become subverted in tumors. She also described how an
integrin that is frequently upregulated in squamous cell
carcinomas helps cells to evade apoptosis. Finally she told
us that aberrant integrin expression in the differentiated
layers of the epidermis can exert a positive or negative
influence on tumor formation in undifferentiated cells that
have mutations in Ras. 
Initiation, growth and invasion 
Whereas Watt is asking about the steps to cancer forma-
tion in individual cells, Doug Hanahan (University of Cali-
fornia, San Francisco, USA) asked why cancer cells seem to
remain loyal to their organ of origin. In an incredibly
elegant approach, Hanahan uses specific promoters to
drive the expression of oncogenes such as SV40 T antigen
in individual cells, such as those of pancreatic islets, in
transgenic mice. One crucial finding has been that abroga-
tion of the tumor suppressors p53 and Rb by tissue-specific
expression of SV40 T antigen is not sufficient to cause
tumor formation in the majority of cells. This is the first
experiment in which it has been possible to follow the for-
mation of a cancer from the beginning (or at least from the
loss of two tumor suppressors). 
Hanahan also addressed the last stage in cancer develop-
ment and the one that has the most effect on the patient:
progression to the invasive phenotype. Building on work
from G. Christofori (Institute of Molecular Pathology,
Vienna, Austria) showing that decreased expression of the
cell-adhesion molecule E-cadherin correlates with carcino-
genesis, Hanahan asked whether extracellular-matrix-asso-
ciated proteases, which also affect cell adhesion, have a role
in cancer progression. Although it appears that the protease
MMP-9 is required for angiogenesis (as it activates the vas-
cular endothelial growth factor, VEGF), the surprising
observation is that neither MMP-9 nor the related protease
MMP-2 is required for invasion of tissues by cancer cells. In
a search for candidate molecules that may have a role in
invasion, Hanahan considered IGF-2, levels of which
increase during tumorigenesis. Loss of IGF-2 does not
inhibit tumor growth but leads to tumors that are benign
and well-defined. In contrast, overexpression of the receptor
for IGF-2 (IGF-R1) gives rise to accelerated and wildly
aggressive tumor formation - and E-cadherin expression is
downregulated, as expected. Hanahan is now applying these
very flexible models to build molecular profiles of the
various stages of tumorigenesis using Affymetrix oligonu-
cleotide microarrays. One interesting observation in the light
of the expected role of proteases in invasion is that, of the
genes whose expression is low in normal cells but high in
tumors, the cathepsin family of cysteine/aspartic acid pro-
teases stands out. Hanahan has therefore developed cathep-
sin inhibitors that he has used in stage-specific ‘therapeutic
trials’ in his mouse models. The compounds show activity at
all stages and appear to be able not only to exert an effect on
cell proliferation (perhaps by affecting angiogenesis) but
also to exert a strong effect on invasiveness. Hanahan has
found that inflammatory cell types (expressing the antigens
Mac1 and GR1) normally express high levels of cathepsins,
which has led to the question, as yet unanswered, of what
contribution inflammatory cells may make in the progres-
sion to invasiveness. 
From cancer genes to cancer drugs 
Paddy Johnston (Queens University, Belfast, UK) discussed
cancer chemotherapy and the best strategies for cancer treat-
ment. Thymidylate synthase (TS) has been a target of cancer
drugs such as fluoropyrimidines and folate analogs for the
last 40 years. Drug resistance in patients is often due to the
upregulation of TS itself. Because p53 is frequently mutated
in cancer cells, Johnston investigated whether the p53
pathway interacts with TS, using a tetracycline-regulated TS
gene expressed in cells expressing or lacking wild-type p53.
His results indicate that both TS levels and p53 status serve
as good predictors of a cell’s response to chemotherapy. On
the strength of this, Johnston has used Affymetrix micro-
arrays to seek genes whose expression changes following
treatment with 5-fluoro-uracil, a fluoropyrimidine drug. He
then asked whether inhibition of the cell death pathway that
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resistance to TS inhibitors, and generated some very
provocative results suggesting that sensitivity and acquired
resistance to TS is very likely to depend upon p53 status and
on regulation of more than one cell death pathway.
Many genes, many targets: one drug 
The opening statement by Paul Workman (Institute for
Cancer Research, Sutton, UK), a champion of translational
cancer research, was that when it comes to cancer therapies,
we can never know enough. If you think you have a good
idea, you just need confidence in the target and to keep on
trying until you can test the hypothesis in the ultimate model
- the cancer patient. In his vision of modern cancer medi-
cine, the identification of cancer genes will allow us to use
diagnostic microarrays to define a patient’s cancer, prognos-
tic arrays to define the appropriate therapy, and bioinfor-
matics to analyze the readouts from clinical trials and
therapeutic regimens on individual patients. These same
technologies will also be applied to the discovery of new
therapeutic agents, although the ultimate goal would be an
individualized strategy for cancer prevention. With regard to
cancer drug discovery, the key issues that Workman consid-
ered were whether the cancer is due to a hard-wired depen-
dency on an oncogene that opens a therapeutic window
between healthy and cancer cells; whether correction of a
single defect will be sufficient for a cure; whether drug resis-
tance is likely to be acquired; and finally whether the inhibi-
tion of several pathways will be required. 
Consideration of these questions led Workman to choose
Hsp90 as a target. Hsp90 is frequently over-expressed in
human cancers and is required for the folding of proteins
such as Erb-B2, the kinases Raf, CDK4 and Polo-1, mutant
p53, the receptor tyrosine kinase Met, human telomerase
reverse transcriptase and nuclear hormone receptors.
Between them, these proteins cover each of the deleterious
events that were called the ‘hallmarks of cancer’ by Hanahan
and R.A. Weinberg in 2000. Loss of Hsp90 function is likely
to lead to the degradation of Hsp90 targets, causing cell-cycle
arrest and/or apoptosis of the cancer cells whose survival
depended on the targets. Despite many of the problems often
associated with drug development - and the additional prob-
lems associated with sceptical colleagues - Workman has
been able to validate Hsp90 as a drug target and initiate clini-
cal trials of two Hsp90 inhibitors, 17AAG and geldanamycin. 
One multi-protein family, many specific drugs? 
The work of Louise Johnson (University of Oxford, UK) is
driven by the idea that the cyclin-dependent protein kinases
(CDKs) are in fact excellent candidate drug targets (contrary
to Tim Hunt’s opinion, mentioned above). This rationale is
justified by the elegant work of Johnson and others who are
dissecting, at the atomic level, exactly how specificity is built
into these basic cellular timekeepers. Using structural infor-
mation, it has been possible to design inhibitors that, at least
in vitro, show a more than 100-fold preference for Cdk2 and
Cdk1 over Cdk4. Given the clinical experience with Gleevec,
a kinase inhibitor and the first drug to be identified using
rational approaches to drug design, such a range of potency
may be sufficient for clinical applications. Although it still
remains to be demonstrated that targeting Cdk1 and/or
Cdk2 is a desirable clinical goal, this work is at least leading
us to the tools we need to be able to do the experiment. 
Johnson moved away from inhibitors of the protein-kinase
activity of Cdk2 to discuss the structural basis for the recog-
nition and binding of substrates by cyclins, the regulatory
subunits of CDKs. Her group are currently building on pub-
lished data to model the interactions of the cyclin-A-Cdk2
complex with peptides derived from a range of its substrates.
The hope is that these studies will lead to a new way of
inhibiting CDKs in which the phosphorylation of only one
tumor-specific substrate will be inhibited. 
One cancer pathway targeted by drugs at many levels 
David Lane (Cyclacel and University of Dundee, UK) fol-
lowed a similar theme, starting from a molecular under-
standing of p53 and proceeding via structural biology to the
in silico identification and engineering of small-molecule
inhibitors of Mdm2, a ubiquitin ligase that targets p53 for
degradation. The idea is that cells in which p53 is stable will
be driven into apoptosis, a process that is frequently defec-
tive in cancer cells. The advantage of focusing on the p53
pathway, from Lane’s perspective, is that there are many
points at which one can intervene: inhibitors of the protea-
some or of Mdm2, or mimics of ARF (an inhibitor of Mdm2)
should all have the same effect: stabilizing wild-type p53,
allowing it to kill tumorigenic cells. One strategy that holds
great hope, yet has still to meet expectations, is the inhibi-
tion of nuclear export: so far, leptomycin B is the only poten-
tial drug that gives rise to the transcriptionally active form of
p53 that will kill cells. The therapies that can activate p53
without inducing DNA damage will work only in the half of
human tumors that retain wild-type p53; other approaches,
such as the CDK inhibitors his group are also developing,
will be needed in cells lacking p53.
Many drugs to regulate one protein 
Bill Kaelin (Dana-Farber Cancer Institute, Boston, USA)
started by giving the background to the genetic von-Hippel-
Lindau (VHL) disease that includes a predisposition to
cancer. One peculiarity of this disease is that although it is
recessive, meaning that both alleles of the VHL disease gene
need to be mutated for the disease to manifest itself, 90% of
cells in which the first allele is inactivated rapidly lose the
second allele. The VHL gene encodes an E3 ubiquitin ligase,
one of the major substrates of which is the normally labile 
subunit of a transcription factor called hypoxia-inducible
factor (HIF). In cells lacking functional VHL, HIF accu-
mulates, leading to the increased production of blood vessels
and red blood cells that are hallmarks of VHL disease. These
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Genome Biology 2003, 4:305processes would usually be regulated by oxygen levels: a
proline residue of HIF is hydroxylated in response to
oxygen, leading to the recruitment of VHL and degradation of
HIF. Kaelin’s group set out to purify the HIF hydroxylase
by traditional methods, but in the meantime the group of
Eugene Koonin (National Center for Biotechnology Informa-
tion, National Institutes of Health, Bethesda, USA) identified
Egln-C in silico as a candidate proline hydroxylase. There are
two human Egln-C homologs and one nematode homolog,
and Kaelin used small inhibitory RNAs (siRNAs) to show that
loss of only one of the human homologs, Egln-1, resulted in
stabilization of HIF. Kaelin then looked at the interplay
between HIF and VHL in cancer formation. Downregulation
of HIF using siRNAs prevented tumor formation, indicating
that stabilization of HIF may be necessary for tumor forma-
tion. In addition, stabilization of HIF by mutation of its
hydroxylated proline to alanine allowed cells to acquire a can-
cerous phenotype even in the presence of wild-type VHL
protein, suggesting that stable HIF may be sufficient to
drive tumor formation. Kaelin’s group has already shown that
inhibitors of some of the proteins whose expression is upreg-
ulated by HIF, such as VEGF, have beneficial clinical effects
in cancers such as metastatic renal carcinoma. Starting from
a genetically simple disease, this work clearly shows that
there may be many ways to prevent tumor growth. 
In summary, this is a time of great hope in cancer research,
given the discovery of Gleevec, the first clinically successful,
rationally identified drug, and now that microarray tech-
nologies are allowing us to identify new pathways and to find
the right therapies for each patient. But rational drug design
still has some way to go: Gleevec was really identified using
only semi-rational methods (the target was chosen, but the
screen was still a random walk through ATP analogs). Simi-
larly, microarrays have only scratched the surface of molecu-
lar characterization of cancers, and we are just beginning to
get a feel for their applications in diagnosis and prognosis.
Tools are needed that will allow us to determine whether a
new protein that is implicated at some stage in cancer really
is a good drug target. The Hutchison/MRC Centre and other
institutes are responding to some of these needs. From the
very high standard of this symposium, the future of transla-
tional cancer research seems bright. 
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